mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000

View company profile
Current Jobs

Health Policy Manager
Location: Nationwide

Oncology Hospital Specialist
Location: South and South West of England

Boehringer Ingelheim begins ovarian cancer trial

Posted on 23/12/2009 in Pharmaceutical Company Product News

Boehringer Ingelheim announced this week that it has started a clinical study into one of its ovarian cancer therapies ? the compound BIBF 1120.

The trial will investigate the novel oral anti-angiogenic agent for its efficacy and safety as a first-line treatment in combination with standard chemotherapy.

Vargatef is the planned brand name for the product, which works by simultaneously inhibiting three receptors involved in the formation of the blood vessels that are needed for tumours to develop and spread.

Andreas du Bois, the international coordinating investigator of this trial, commented: "Anti-angiogenic compounds are one of the most promising new approaches in treating cancer, and ovarian cancer appears to be particularly sensitive to these novel agents, as suggested by early clinical trials."

Meanwhile, Boehringer-Ingelheim revealed last month that Micardis (telmisartan) - its treatment for the reduction of cardiovascular morbidity risk - was approved by the European commission.

Other news stories from 23/12/2009

Read more in the Zenopa News Archive

How this news is generated

Claire
Account Manager
for this opportunity

01494 818 025
(Mon to Fri 0830 to 1800 hours)
claire@zenopa.com

Latest News

Boehringer Ingelheim to acquire SSP

Boehringer Ingelheim piglet castration product approved in EU

Boehringer Ingelheim to collaborate with Priaxon

Boehringer Ingelheim begins ovarian cancer trial

Boehringer-Ingelheim reveals EC approval of Micardis

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use